Sponsor pipeline

Yana Najjar clinical trial pipeline

Get alerts when Yana Najjar's trials change

6 active trials 3 recruiting 1 disease areas

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-11

What changed in the last 30 days

First postedNew trial filingPhaseStatus
2026-10-07 NCT07862530 Neoadjuvant RP2 + Nivolumab in Patients With Melanoma Phase 2 Not Yet Recruiting

Active trials by phase

Early Phase 1
1
Phase 1
2
Phase 2
1
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2
NCT07862530 Neoadjuvant RP2 + Nivolumab in Patients With Melanoma MelanomaCutaneous Melanoma Resectable, Melanoma Not Yet Recruiting 2026-10-07
Phase 1
NCT04572451 Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in… Melanoma Active, Not Recruiting 2026-08-20
NCT03311308 A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma Advanced Melanoma Active, Not Recruiting 2026-06-30
Early Phase 1
NCT06216938 RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis Melanoma Recruiting 2026-04-13
Not specified
NCT04658303 Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma Melanoma Recruiting 2026-06-11
NCT06831071 Evaluation of Hypoxia in Primary Melanoma Melanoma Recruiting 2026-06-10

Disease areas by active trials

Melanoma (6)

Get alerts when Yana Najjar's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free